“Hopefully, this statement will enable health-care providers to offer those women in midlife, who may benefit from MHT, the opportunity to make an informed decision”.1

Umbrella
What may the Hormone Therapy 2016 Revised Global Consensus Statement Umbrella include?

Depending on the Source (DotS) this Umbrella may include:

  • Hormone Replacement Therapy (HRT)
  • Hormone Therapy (HT)
  • Menopausal Hormone Therapy (MHT)
  • Revised Global Consensus Statement on Menopausal Hormone Therapy

Revised Global Consensus Statement

What is the Revised Global Consensus Statement on Menopausal Hormone Therapy?

In the Revised Global Consensus Statement on Menopausal Hormone Therapy (Revised Global Consensus Statement) – endorsed by seven menopause-related organizations – published online 20 June 2016, the authors explain:

Hormone Therapy 2016 Revised Global Consensus Statement

“The publication of the Global Consensus on Menopausal Hormone Therapy in 2013 by leading global menopause societies succeeded in presenting guidelines in a troubled therapeutic area that are helpful to both health-care providers and potential users of menopausal hormone therapy (MHT). The revised statement is aimed at updating and expanding the areas of consensus”.2

Organizations

Which organizations endorse the Revised Global Consensus Statement?

Organizations which endorse the Revised Global Consensus Statement (in alphabetical order) are the:

Organizations

  1. Asia Pacific Menopause Federation
  2. Endocrine Society
  3. European Menopause and Andropause Society
  4. Federation of Latin American Menopause Societies
  5. International Menopause Society
  6. International Osteoporosis Foundation
  7. North American Menopause Society

Hopeful

What are the Revised Global Consensus Statement authors hopeful of?

The Revised Global Consensus Statement authors note:

“Hopefully, this statement will enable health-care providers to offer those women in midlife, who may benefit from MHT, the opportunity to make an informed decision”.3

Acknowledgement

What do the Revised Global Consensus Statement authors acknowledge?

The Revised Global Consensus Statement authors acknowledge:

“The revised statement contains only areas of consensus and does not replace the more detailed and fully referenced recommendations of the individual societies (referenced at the end of the document)”.4

Consensus

What are some points of consensus in the Revised Global Consensus Statement?

Some points of consensus are:

  • “MHT, including tibolone and the combination of conjugated equine estrogens and bazedoxifene (CE/BZA), is the most effective treatment for vasomotor symptoms (VMS) associated with menopause at any age, but benefits are more likely to outweigh risks if initiated for symptomatic women before the age of 60 years or within 10 years after menopause
  • If MHT is contraindicated or not desired for treatment of VMS, selective serotonin reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors such as paroxetine, escitalopram, venlafaxine and desvenlafaxine, which have been shown to be effective in randomized controlled trials (RCTs), may be considered. Gabapentin may also be considered
  • Local low-dose estrogen therapy is preferred for women whose symptoms are limited to vaginal dryness or associated discomfort with intercourse or for the prevention of recurrent urinary tract infections”.5

Vasomotor Symptoms

What are vasomotor symptoms?

DotS the definition of vasomotor symptoms may vary. The North American Menopause Society’s definition is:

“Vasomotor symptoms. Also known as hot flashes and night sweats, common symptoms during perimenopause and early postmenopause”.6

Health Care Provider

What if I choose to use MHT?

If you choose to use MHT, it may be in your best interest to also choose to talk to your health care provider about this.

One of the points of consensus in the Revised Global Consensus Statement is:

  • “The option of MHT is an individual decision in terms of quality of life and health priorities as well as personal risk factors such as age, time since menopause and the risk of VTE, stroke, ischemic heart disease and breast cancer. MHT should not be recommended without a clear indication for its use”.7

What is VTE?

MHT can be an abbreviation for Venous Thromboembolism.

Health Topics A-Z

Where may I find Health Topics related to Hormone Therapy 2016 Global Consensus Statement?

In Health Topics A-Z you may find:

Links

Where may I find Links related to Hormone Therapy 2016 Global Consensus Statement?

Your Country may have Links similar to:

Sources

Where may I find the Sources quoted above?

You may find the Sources at:

Sources

  1. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 12 February 2020
  2. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 12 February 2020
  3. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 12 February 2020
  4. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Introduction. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 12 February 2020
  5. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section A: Benefit/Risk Profile of MHT. Climacteric, 2016;19:4:313 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 12 February 2020
  6. Menopause Glossary: V – Vasomotor Symptoms. North American Menopause Society http://www.menopause.org/for-women/menopause-glossary#V Accessed: 12 February 2020
  7. De Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C. and Pierroz, D. D. Revised Global Consensus Statement on Menopausal Hormone Therapy: Section B: General Principles Governing the Use of MHT. Climacteric, 2016;19:4:314 https://www.imsociety.org/manage/images/pdf/ba6379e868044bec13015ac2b84f2753.pdf Accessed: 12 February 2020
Topic Last Updated: 12 February 2020 – Topic Last Reviewed: 12 February 2020
image_pdf